Nearly 700 bottles of a popular ACE inhibitor are being recalled after it failed an Organic Impurities Test. The drug was manufactured in India and then distributed by New Jersey-based Rising Pharma Holdings.

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

The issue at the heart of this recall has been linked to three patient deaths. 

Stryker Sustainability Solutions is recalling more than 8,000 reprocessed medical devices. This is a Class II recall, according to the FDA, and these devices should no longer be used to treat patients.

Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 

The physician was accused of pressuring Medicare patients into undergoing treatment they did not need. One patient allegedly received 42 different stents over an eight-year period.

Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

The company's Seismiq platform has already gained FDA approval for treating PAD. This new analysis highlights its potential to treat calcified coronary lesions during PCI procedures.

As CCTA sees rapid adoption across cardiology, SCCT is working to address the education required to sustain the expansion.